UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: November 2026
Commission file number: 001-41557
CLEARMIND
MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
CONTENTS
Attached hereto and incorporated
herein is the Registrant’s press release issued on November 16, 2026, titled “Clearmind Achieves Full Enrollment for Part
C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone.”
The first three paragraphs
of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration
Statements on Form F-3 (File Nos. 333-275991,
333-270859, 333-273293,
333-290404, 333-293521
and 333-295455) and Form S-8
(File No. 333-283695), filed
with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded
by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release titled: “Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone” |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Clearmind Medicine, Inc. |
| |
(Registrant) |
| |
|
|
| Date: November 16, 2026 |
By: |
/s/ Adi Zuloff-Shani |
| |
Name: |
Adi Zuloff-Shani |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase
I/IIa Trial, Marking Key Clinical Milestone
Vancouver, Canada, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine
Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic
psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use
Disorder (“AUD”), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I/IIa clinical
trial evaluating CMND-100.
The completion of patient enrollment for Part C marks another important
milestone in Clearmind’s clinical development program and reflects the continued strong execution of its Phase I/IIa trial. The
achievement follows the successful enrollment of the first cohort in Part B, representing the first clinical evaluation of CMND-100 in
patients with moderate-to-severe AUD, and builds on the encouraging safety and tolerability data from Part A in healthy volunteers.
Part C is a randomized, double-blind, placebo-controlled multiple-dose
study designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100. The trial is being conducted at premier clinical
research sites across the United States and Israel, including Johns Hopkins University School of Medicine, Yale School of Medicine, Tel
Aviv Sourasky Medical Center, and Hadassah Medical Center.
“The successful completion of Part C enrollment demonstrates
the continued momentum of our CMND-100 program and represents another important milestone for Clearmind,” said Dr. Adi Zuloff-Shani,
Chief Executive Officer of Clearmind Medicine. “The data generated in this cohort is expected to further enhance our understanding
of CMND-100’s safety, tolerability, and pharmacokinetic profile to help support the advancement of our proprietary non-hallucinogenic
treatment candidate toward future development milestones.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic,
second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.
Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines,
foods, or supplements.
The Company’s intellectual property portfolio currently consists
of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted
and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol
“CMND.”
For further information, visit: https://www.clearmindmedicine.com or
contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions
or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements
when it discusses the anticipated data from Part C of the Phase I/IIa clinical trial, the potential for such data to further inform the
Company’s understanding of CMND-100’s safety, tolerability and pharmacokinetic profile, and the continued clinical development
and advancement of CMND-100 toward future development milestones. Forward-looking statements are not historical facts, and are based upon
management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations,
beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs
and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ
materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting
the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”),
including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October
31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company
assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates
with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience,
and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible
for the contents of third-party websites.